Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Completed 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 279Thoracic 14Head & Neck 9Tumor-Agnostic 6Other solid neoplasm 6Breast 3Genitourinary 2NET 1Gynecologic 1Endocrine 1

Conditions

Adenocarcinoma 3Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
S 1 (combination) × Tumor-Agnostic × Clear all
NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Ruijin Hospital

Phase 2 Active not recruiting
80 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Ruijin Hospital

Phase 2/3 Active not recruiting
580 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT00400023 2024-09-03

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

NCT05237349 2024-01-05

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

Jiangsu Cancer Institute & Hospital

Phase 2 Unknown
38 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02564367 2021-04-29

S-1 adjuvant

AIO-Studien-gGmbH

Phase 1/2 Completed
30 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT00479076 2011-01-26

A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients

Sanofi

Phase 1 Completed
22 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡